GAD2

GAD2

GAD2 Molekülinformation

Molecule Name
Glutamate decarboxylase 2
Molekülalias
GAD2,GAD65,Glutamate decarboxylase 2
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePending
Target-Alias
EC 4.1.1.15,GAD65,Glutamate Decarboxylase 2 (Pancreatic Islets And Brain, 65kD),Glutamate Decarboxylase-2 (Pancreas),EC:4.1.1.15,EC 4.1.1,Glutamate decarboxylase 65 kDa isoform,65 kDa glutamic acid decarboxylase,GAD2,Glutamate Decarboxylase 2,Glutamate Decarboxylase 2 (Pancreatic Islets And Brain, 65kDa),GAD-65
Molekülhintergrund
Glutamate decarboxylase or glutamic acid decarboxylase (GAD) is an enzyme that catalyzes the decarboxylation of glutamate to gamma-aminobutyric acid (GABA), the major inhibitory transmitter in higher brain regions, and putative paracrine hormone in pancreatic islets. GAD uses pyridoxal-phosphate (PLP) as a cofactor.Two molecular forms of GAD (65 kDa and 67 kDa) are highly conserved and both are expressed in the CNS, pancreatic islet cells, testis, oviduct and ovary. The isoforms are regionally distributed cytoplasmically in the brains of rats and mice. GAD65 is an ampiphilic, membrane-anchored protein (585 a.a.), and is responsible for vesicular GABA production. GAD67 is cytoplasmic (594 a.a.), and seems to be responsible for significant cytoplasmic GABA production.

GAD2 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
KLS-2031KLS-2031Kolon Life Science. Inc
Details